{'fraction_non_alphanumeric': 0.02681992337164751, 'fraction_numerical': 0.011494252873563218, 'mean_word_length': 5.792207792207792, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
PD‐L1 expression in tumour‐infiltrating lymphocytes is a poor prognostic factor for primary acral melanoma patients

Programmed cell death protein 1–programmed death‐ligand 1 (PD‐L1) blockade immunotherapy has shown notable therapeutic benefit in metastatic melanoma, but the clinical relevance of PD‐L1 expression remains unclear in melanoma, especially in acral melanoma, which is the most common subtype in Asians. The aim of this study was to evaluate the clinical effect of PD‐L1 expression in primary acral melanoma.